Chronic Kidney Disease

Pharmacy Times will be covering the American Society of Nephrology (ASN) Kidney Week, which will be gathering more than 10,000 professionals working on kidney health in Orlando, Florida.

Pharmacy Times is gearing up for Kidney Week (Nov. 3-6) by learning about the pharmacological role of kidney care from the president of the American Society of Nephrology.

The estimation of glomerular filtration rate based on cystatin C could provide a more robust prediction of cardiovascular disease and mortality in patients.

The objective of the trial was to compare letermovir with valganciclovir in preventing CMV disease in adults who received a kidney transplant and who are at high risk for CMV disease.

SGLT-2 inhibitors, GLP-1 receptor agonists, and a non-steroidal mineralocorticoid receptor are all showing promise in the prevention and management of diabetic kidney disease.

New research suggests that high levels of an immune protein in kidney disease might be able to predict risk of heart failure or death by reflecting the upstream process of stress.

The study confirmed that patients with psoriasis are considered to have an increased risk for both chronic kidney disease and ESRD, because inflammation plays a significant role in those conditions as well as heart disease.

Panelists at the AMCP Nexus conference discuss the burden of undertreated and untreated chronic kidney disease.

Although survival benefits for patients who received a kidney transplant varied, the benefits of kidney transplants were greater for all patients when compared with long-term dialysis.

Understanding long-term frailty trajectories with kidney function measures could help prevent worse adverse health outcomes in older patients.

Investigators combine research discovery with technological development to determine whether the role of genomics in nephrology should remain with subspecialists or be integrated into general nephrology.

Innovative system reveals a pair of potential therapies for autosomal recessive polycystic kidney disease, which currently has no FDA-approved treatments.

The drug improves kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.

Modification is based on phase 3 FIGARO-DKD clinical trial investigating CV and kidney outcomes in more than 13,000 patients with CKD associated with type 2 diabetes.

The findings also indicate that that treatment may have protective CV and limb benefits for those with kidney failure and concomitant peripheral artery disease.

Early detection of chronic kidney disease is vital to preventing comorbid conditions.

The phase 2 study will evaluate the efficacy and safety of 2 different doses of MK-2060 in patients with ESRD receiving hemodialysis via an arteriovenous graft.

Uric Acid Cleanse helps to managing uric acid levels for kidney support.

A new study warns that fluoroquinolone could increase the risk of altered mental status and hospitalizations for advanced chronic kidney disease patients, though it is rare.

Kayexalate is a potassium binder indicated for the treatment of hyperkalemia.

American Diabetes Association updates recommendations regarding SGLT-2 inhibitors, GLP-1 RA, and finerenone for cardiovascular and renal comorbidities.

Compared to atorvastatin, rosuvastatin was associated with higher risks of blood in the urine and kidney failure that requires replacement therapy.

Belimumab (Benlysta) the first FDA-approved therapy for pediatric lupus nephritis.

Methotrexate is an immunosuppressive agent used to treat cancer, dermatology-, and rheumatology-related issues.

Expanded glomerular filtration rate (GFR) testing in the United States could be one step toward minimizing disparities in renal formulas, Beumer said.

Tolvaptan (Jynarque )is a selective vasopressin V2-receptor antagonist .

The ability to measure GFR would be a significant advancement for clinicians in the United States.

Renvela is a phosphate binder indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.

Approved by the FDA in 2021, finerenone is the only non-steroidal mineralocorticoid receptor antagonist that reduces the risk of renal disease progression and cardiovascular events in adults with type 2 diabetes mellitus-mediated chronic kidney disease.

The use of certain drugs, such as statins, may lead to rhabdomyolysis.